BBNX BETA BIONICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BETA BIONICS INC reported revenue of $32.0M (up 37.8% from a year earlier), net income of −$23.4M and diluted EPS of −$0.53; over the last four quarters revenue was $119M and net income −$73.0M; for the fiscal year ended December 2025 revenue was $100M, up 53.9% on the year before.
BBNX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $100M, gross profit $55.5M, operating income −$71.7M, net income −$73.2M (margin -73.0%), EPS −$1.81
- Fiscal year ended Dec 2024: revenue $65.1M, gross profit $35.9M, operating income −$45.3M, net income −$54.8M (margin -84.1%), EPS −$8.60
- Fiscal year ended Dec 2023: revenue $12.0M, gross profit $6.31M, operating income −$35.9M, net income −$44.1M (margin -367.6%), EPS −$8.31
BBNX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $32.0M (up 37.8% year over year), net income −$23.4M, EPS −$0.53
- Quarter ended Mar 31, 2026: revenue $27.6M (up 56.6% year over year), net income −$21.9M, EPS −$0.49
- Quarter ended Dec 31, 2025 (from the annual report): revenue $32.1M (up 57.1% year over year), net income −$13.5M, EPS −$0.16
- Quarter ended Sep 30, 2025: revenue $27.3M (up 63.1% year over year), net income −$14.2M, EPS −$0.33
- Quarter ended Jun 30, 2025: revenue $23.2M (up 54.4% year over year), net income −$16.9M, EPS −$0.39
- Quarter ended Mar 31, 2025: revenue $17.6M (up 36.4% year over year), net income −$28.7M, EPS −$0.93
- Quarter ended Dec 31, 2024 (from the annual report): revenue $20.4M, net income −$18.1M, EPS −$2.70
- Quarter ended Sep 30, 2024: revenue $16.7M, net income −$9.74M, EPS −$1.46
- Quarter ended Jun 30, 2024: revenue $15.0M, net income −$14.5M, EPS −$2.37
- Quarter ended Mar 31, 2024: revenue $12.9M, net income −$12.4M, EPS −$2.07
BBNX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$50.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$48.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.4M, share buybacks n/a
BBNX balance sheet
- Jun 30, 2026: cash $44.3M, total assets $292M, total liabilities $36.0M, shareholders' equity $256M
- Mar 31, 2026: cash $30.2M, total assets $304M, total liabilities $33.2M, shareholders' equity $271M
- Dec 31, 2025: cash $31.6M, total assets $329M, total liabilities $41.1M, shareholders' equity $288M
- Sep 30, 2025: cash $38.5M, total assets $330M, total liabilities $35.3M, shareholders' equity $295M
- Jun 30, 2025: cash $35.1M, total assets $330M, total liabilities $28.3M, shareholders' equity $302M
- Mar 31, 2025: cash $42.5M, total assets $338M, total liabilities $24.3M, shareholders' equity $314M
- Dec 31, 2024: cash $30.4M, total assets $150M, total liabilities $73.6M, shareholders' equity −$245M
- Dec 31, 2023: cash $26.6M, total assets $110M, total liabilities $51.4M, shareholders' equity −$203M
What is BBNX's revenue?
BETA BIONICS INC reported $119M of revenue over its last four quarters, through June 30, 2026.
Is BBNX profitable?
No. BETA BIONICS INC lost $73.0M over the last four quarters.
What is BBNX's EPS?
Diluted earnings per share over the last four quarters were −$1.51; −$0.53 in the latest quarter.